Royalty Pharma Earnings
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Wed, Nov 4, 2026
Fiscal period
Sep/2026
EPS estimate
$1.18
Royalty Pharma earnings summary
Royalty Pharma is scheduled to report Sep/2026 earnings on Nov 4, 2026, with analysts expecting EPS of $1.18. In its most recent report on Aug 5, 2026 (Q2 2026), RPRX posted EPS of $0.04. Revenue for the quarter was $674.1 million.
Quarterly EPS is down 42.9% from the same quarter a year earlier. Across the last 16 reports, RPRX shares moved an average of 2.8% (in either direction) in the first trading session after results, rising 7 times and falling 9 times.
Summary generated from market data by MetaCap's automated system. Methodology
RPRX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $0.04 | — | +3.2% |
| May 6, 2026 | — | $0.67 | — | +4.1% |
| Feb 11, 2026 | — | $0.49 | — | -0.2% |
| Nov 5, 2025 | — | $0.67 | — | +1.6% |
| Aug 6, 2025 | — | $0.07 | — | -3.3% |
| May 8, 2025 | — | $0.55 | — | +2.6% |
| Feb 12, 2025 | — | $0.46 | — | +3.3% |
| Nov 6, 2024 | — | $1.21 | — | -1.9% |
| Aug 8, 2024 | — | $0.23 | — | +3.5% |
| May 9, 2024 | — | $0.01 | — | -2.9% |
| Feb 15, 2024 | — | $1.11 | — | +3.7% |
| Nov 8, 2023 | — | $0.16 | — | -2.3% |
| Aug 8, 2023 | — | $0.50 | — | -3.7% |
| May 9, 2023 | — | $0.76 | — | -2.4% |
| Feb 15, 2023 | — | $-1.04 | — | -3.9% |
| Nov 8, 2022 | — | $0.32 | — | -2.4% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.